Market News

Crescent Park Management LP Has Upped Fleetcor Technologies (FLT) Stake; University Of Notre Dame Du Lac Trimmed By $1.18 Million Its Clovis Oncology (CLVS) Position

Crescent Park Management Lp increased Fleetcor Technologies Inc (FLT) stake by 68.66% reported in 2017Q3 SEC filing. Crescent Park Management Lp acquired 47,481 shares as Fleetcor Technologies Inc (FLT)’s stock declined 18.44%. The Crescent Park Management Lp holds 116,634 shares with $18.05M value, up from 69,153 last quarter. Fleetcor Technologies Inc now has $18.32 billion valuation. The stock increased 0.57% or $1.15 during the last trading session, reaching $204.55. About 171,639 shares traded. FleetCor Technologies, Inc. (NYSE:FLT) has declined 6.67% since January 18, 2017 and is downtrending. It has underperformed by 23.37% the S&P500.

University Of Notre Dame Du Lac decreased Clovis Oncology Inc (CLVS) stake by 28.23% reported in 2017Q3 SEC filing. University Of Notre Dame Du Lac sold 14,366 shares as Clovis Oncology Inc (CLVS)’s stock declined 20.61%. The University Of Notre Dame Du Lac holds 36,529 shares with $3.01 million value, down from 50,895 last quarter. Clovis Oncology Inc now has $2.72 billion valuation. The stock increased 1.09% or $0.6 during the last trading session, reaching $55.53. About 717,457 shares traded. Clovis Oncology, Inc. (NASDAQ:CLVS) has risen 282.71% since January 18, 2017 and is uptrending. It has outperformed by 266.01% the S&P500.

Since August 4, 2017, it had 0 buys, and 7 selling transactions for $2.78 million activity. On Tuesday, August 15 IVERS-READ GILLIAN C sold $210,150 worth of Clovis Oncology, Inc. (NASDAQ:CLVS) or 3,000 shares. SPICKSCHEN THORLEF had sold 4,500 shares worth $292,365. On Friday, August 4 BLAIR JAMES C sold $1.45 million worth of Clovis Oncology, Inc. (NASDAQ:CLVS) or 18,450 shares.

Investors sentiment decreased to 1.44 in Q3 2017. Its down 0.37, from 1.81 in 2017Q2. It turned negative, as 48 investors sold CLVS shares while 49 reduced holdings. 42 funds opened positions while 98 raised stakes. 47.46 million shares or 2.14% more from 46.46 million shares in 2017Q2 were reported. Public Employees Retirement Association Of Colorado has 7,578 shares. Palo Alto Ltd Com reported 3.33 million shares. 72,888 are held by Jane Street Ltd. Parallax Volatility Advisers Limited Partnership has invested 0% in Clovis Oncology, Inc. (NASDAQ:CLVS). Smith Asset Mgmt Group Inc Limited Partnership invested in 8,050 shares. Fincl Bank Of New York Mellon Corp invested in 0.01% or 275,326 shares. Northern Trust Corp stated it has 572,755 shares or 0.01% of all its holdings. Tocqueville Asset Ltd Partnership reported 0.08% of its portfolio in Clovis Oncology, Inc. (NASDAQ:CLVS). Int Grp holds 0.01% of its portfolio in Clovis Oncology, Inc. (NASDAQ:CLVS) for 29,044 shares. Columbia Wanger Asset Mngmt Ltd Liability stated it has 0.71% of its portfolio in Clovis Oncology, Inc. (NASDAQ:CLVS). Prelude Management Ltd Llc reported 7,967 shares. Morgan Stanley reported 198,903 shares. California State Teachers Retirement Systems owns 70,356 shares or 0.01% of their US portfolio. State Board Of Administration Of Florida Retirement System reported 0.01% stake. Janney Montgomery Scott Ltd Liability invested 0.01% in Clovis Oncology, Inc. (NASDAQ:CLVS).

Among 20 analysts covering Clovis Oncology (NASDAQ:CLVS), 14 have Buy rating, 0 Sell and 6 Hold. Therefore 70% are positive. Clovis Oncology had 54 analyst reports since September 10, 2015 according to SRatingsIntel. The stock of Clovis Oncology, Inc. (NASDAQ:CLVS) earned “Neutral” rating by Mizuho on Monday, November 16. Piper Jaffray upgraded Clovis Oncology, Inc. (NASDAQ:CLVS) on Thursday, January 26 to “Overweight” rating. Stifel Nicolaus maintained the shares of CLVS in report on Friday, February 26 with “Buy” rating. The company was maintained on Monday, January 25 by Mizuho. The firm earned “Buy” rating on Thursday, September 10 by WallachBeth Capital. As per Friday, August 5, the company rating was initiated by Suntrust Robinson. The stock has “Buy” rating by Leerink Swann on Monday, September 18. J.P. Morgan maintained it with “Buy” rating and $7200 target in Thursday, June 1 report. The company was upgraded on Wednesday, May 17 by JP Morgan. The rating was upgraded by Janney Capital to “Buy” on Tuesday, June 20.

University Of Notre Dame Du Lac increased Advansix Inc stake by 12,075 shares to 147,653 valued at $5.87 million in 2017Q3. It also upped Post Hldgs Inc (NYSE:POST) stake by 6,029 shares and now owns 110,663 shares. Biomarin Pharmaceutical Inc (NASDAQ:BMRN) was raised too.

Analysts await Clovis Oncology, Inc. (NASDAQ:CLVS) to report earnings on February, 28. They expect $-1.27 EPS, up 30.60% or $0.56 from last year’s $-1.83 per share. After $-1.24 actual EPS reported by Clovis Oncology, Inc. for the previous quarter, Wall Street now forecasts 2.42% negative EPS growth.

Among 17 analysts covering Fleetcor Technologies (NYSE:FLT), 15 have Buy rating, 0 Sell and 2 Hold. Therefore 88% are positive. Fleetcor Technologies had 50 analyst reports since August 6, 2015 according to SRatingsIntel. Jefferies maintained it with “Buy” rating and $197 target in Wednesday, April 5 report. JP Morgan maintained it with “Overweight” rating and $138 target in Friday, May 5 report. Jefferies maintained FleetCor Technologies, Inc. (NYSE:FLT) rating on Thursday, May 25. Jefferies has “Buy” rating and $197 target. The rating was maintained by Oppenheimer with “Buy” on Wednesday, November 1. The firm has “Outperform” rating by Keefe Bruyette & Woods given on Monday, September 14. The firm has “Buy” rating given on Friday, March 18 by Evercore. The stock of FleetCor Technologies, Inc. (NYSE:FLT) earned “Hold” rating by Evercore on Wednesday, September 30. The company was maintained on Wednesday, August 19 by Oppenheimer. The rating was maintained by Barclays Capital on Wednesday, September 21 with “Overweight”. Wells Fargo maintained the stock with “Buy” rating in Wednesday, January 10 report.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *